Core Viewpoint - The Hong Kong innovative drug sector is experiencing strong performance, with significant stock price increases for several companies in the industry [1] Company Performance - Sanofi Pharmaceutical (01530.HK) increased by 10.11%, reaching HKD 33.76 [1] - Innovent Biologics (02096.HK) rose by 7.52%, trading at HKD 14.02 [1] - BeiGene (06160.HK) saw a 7.34% increase, with shares priced at HKD 228.2 [1] - China Biologic Products (01177.HK) gained 6.79%, now at HKD 7.39 [1] - I-Mab (01801.HK) experienced a 6.37% rise, with shares at HKD 92.7 [1]

Group 1 - The innovative drug sector has shown strong performance, with notable stock increases for companies such as Sangamo Therapeutics (up 10.11%), Innovent Biologics (up 7.52%), BeiGene (up 7.34%), China Biologic Products (up 6.79%), and I-Mab (up 6.37%) [1] - In Q3, the innovative drug sector reported a revenue growth of 1.98% year-on-year and a net profit attributable to the parent company increased by 7.25% year-on-year [1] - Despite adjustments since September, the overall trend for the innovative drug industry remains positive, supported by domestic policy and the Federal Reserve entering a rate-cutting cycle, with a significant number of licensing deals expected in the next six months to a year [1] Group 2 - Guotai Junan Securities noted that the innovative drug sector continued to experience high revenue growth and profitability turnaround in Q3, indicating a long-term positive development trend for China's innovative drug industry [2] - The explosive growth in business development (BD) transactions has been a key highlight in recent years for the domestic innovative drug sector [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with the progress of partners in overseas development and subsequent global clinical data readings enhancing the commercial certainty of products in the global market [2]

Group 1 - The innovative drug sector shows strong performance, with notable stock price increases for companies such as 三生制药 (up 10.11%), 先声药业 (up 7.52%), and 百济神州 (up 7.34%) [1] - In Q3, the innovative drug sector's revenue grew by 1.98% year-on-year, while net profit attributable to shareholders increased by 7.25% year-on-year [1] - Despite adjustments since September, the overall trend for the innovative drug industry remains positive, supported by domestic policies and the Federal Reserve entering a rate-cutting cycle [1] Group 2 - The innovative drug sector continued to experience high revenue growth and profitability turnaround in Q3, indicating a long-term positive development trend [2] - The surge in business development (BD) transactions highlights the growth potential of the Chinese innovative drug industry [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with subsequent clinical data enhancing commercial certainty in global markets [2]

11月13日，港A两市创新药板块同步走强，延续了本周以来的连续上涨态势。 自8月下旬经历一轮震荡回调后，该板块近期景气度持续攀升，本周累计涨幅已超过4%，市场情绪明显回 暖。 盘面上，A股创新药板块表现活跃。截至发稿，富祥药业强势20CM涨停，盘龙药业涨停；超4600亿市值的 龙头股百济神州因三季度业绩成功扭亏涨超3%。 此外，海辰药业、益方生物、热景生物、一品红、三生国健、迈威生物等个股均大幅跟涨。 | 代码 | 名称 | 现价 | 涨跌 | 涨幅� | | --- | --- | --- | --- | --- | | 300497 | 富祥药业 | 17.50 | | +2.92 +20.03% | | 688068 | 执景生物 | 171.68 | | +18.89 +12.36% | | 300584 | 海辰药业 | 59.85 | | +5.60 +10.32% | | 002864 | 盘龙药业 | 39.20 | | +3.56 +9.99% | | 688382 | 益方生物-U | 28.91 | +2.61 | +9.92% | | 301201 | 诚大药业 | 39.40 | + ...

Core Insights - The innovative drug ETF Tianhong (517380) has seen significant trading activity, with a transaction volume of 34.38 million yuan and a strong index performance, reflecting a 3.66% increase in the Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50 Index [1] - The introduction of a commercial insurance innovative drug directory marks a significant step in China's multi-tiered medical security system, aimed at improving the accessibility and affordability of high-priced innovative drugs [2] - BeiGene reported a turnaround in profitability for the third quarter of 2025, achieving a net profit of 689 million yuan, driven by strong sales of its flagship product, Zanubrutinib [2] - Citic Securities anticipates a stable growth trend in the pharmaceutical industry, supported by policy initiatives and a return to a market pricing system based on clinical value and demand [3] Group 1: ETF Performance - The innovative drug ETF Tianhong (517380) reached a new high in scale at 1.398 billion yuan as of November 12, with a net inflow of 83.52 million yuan over the past ten trading days [1] - The ETF covers the entire industry chain from preclinical research to commercialization, capturing opportunities in the innovative drug sector [1] Group 2: Policy Developments - The recent conclusion of the national medical insurance negotiations and the introduction of a commercial insurance innovative drug directory are expected to enhance the market for high-value innovative drugs [2] - The new directory will focus on rare disease medications and unique innovative drugs, potentially breaking existing sales bottlenecks [2] Group 3: Company Performance - BeiGene's third-quarter revenue reached 10.077 billion yuan, a year-on-year increase of 41.1%, with a total revenue of 27.595 billion yuan for the first three quarters, reflecting a 44.2% growth [2] - The global sales of Zanubrutinib amounted to 7.423 billion yuan in the third quarter, with the U.S. market contributing 5.266 billion yuan, highlighting strong demand in the hematologic oncology sector [2] Group 4: Market Outlook - The pharmaceutical industry is expected to benefit from a stable and continuous growth trend, driven by supportive policies and a focus on clinical value [3]

Core Viewpoint - BeiGene reported a 41% year-on-year revenue growth to $1.41 billion, with non-GAAP net profit reaching $125 million, exceeding market expectations [1] Group 1: Financial Performance - Revenue increased by 41% to $1.41 billion [1] - Non-GAAP net profit reached $125 million, surpassing market forecasts [1] Group 2: Future Projections - Based on the rapid growth of zanubrutinib sales and effective cost control, the profit forecast for 2025 has been raised by 56% to $331 million [1] - The profit forecast for 2026 remains unchanged [1] Group 3: Ratings and Target Prices - The company maintains an "outperform" rating [1] - Target prices for A-shares, H-shares, and US shares have been adjusted upwards by 3.2%, 3.3%, and 3.7% respectively, to 320 CNY, 250 HKD, and 420 USD [1]

Market Overview - The Hong Kong stock market opened lower after three consecutive days of gains, with the Hang Seng Index at 26,779.48 points, down 143.25 points, a decline of 0.53% [1] - The Hang Seng Technology Index reported a decrease of 48.77 points, down 0.82%, reaching 5,885.22 points [2] Company Earnings Reports - BeiGene (06160.HK) reported a revenue of 27.595 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 44.2%. The net profit attributable to shareholders was 1.139 billion yuan, with earnings per share at 0.81 yuan. The net profit for the third quarter alone was 689 million yuan [4] - Tencent Music (01698.HK) announced a total revenue of 8.46 billion yuan for the third quarter, reflecting a year-on-year growth of 20.6%. The net profit was 2.15 billion yuan, up 36.0%. However, the monthly active users for online music services decreased to 551 million [6] - Chow Tai Fook (06168.HK) reported a 32% year-on-year growth in e-commerce revenue for the first ten months, with a net profit increase of 71% and a net profit margin exceeding 8% [7] Stock Performance - BeiGene's stock surged by 7.7% yesterday and opened 4.61% higher today, with a current increase of over 6%, reaching a new high since 2021. Haitong International raised its revenue forecasts for BeiGene for 2025-2027 to 5.3 billion, 6.4 billion, and 7.1 billion USD, respectively, with a corresponding three-year revenue CAGR of 23% [5] - Despite Tencent Music's revenue growth, its stock price fell significantly, with a decline of over 10% as of the latest update [6] Sector Insights - Haitong International emphasized that technology stocks remain a key focus, while招商证券 suggested attention on AI-related internet sectors and humanoid robotics [8] - The Hang Seng High Dividend Yield Index offers a dividend yield of approximately 6%, making it attractive to long-term funds amid an "asset shortage" environment [8]

Group 1 - The core viewpoint of the news highlights the continuous rise of innovative drugs in the Hong Kong stock market, driven by strong performance from companies like BeiGene and 3SBio, leading to a significant increase in the Hang Seng Innovative Drug ETF [1] - BeiGene reported Q3 revenue of 10.077 billion yuan, a year-on-year increase of 41.1%, and a net profit of 689 million yuan, marking a turnaround from losses [1] - The innovative drug sector is experiencing fundamental improvements due to policy support, performance realization, and accelerated international expansion, indicating significant mid-to-long-term investment value [1] Group 2 - A breakthrough in policy is noted with the introduction of a "commercial insurance innovative drug catalog" in the 2025 national medical insurance negotiations, which is expected to improve cash flow for pharmaceutical companies and optimize the payment ecosystem for innovative drugs [1] - The performance of leading pharmaceutical companies in Q3 2025 shows a transition from a "research and development investment phase" to a "commercialization harvest phase," with significant reductions in losses or profitability being achieved [1] - The international expansion of Chinese innovative drugs is accelerating, with total foreign licensing transactions exceeding 100 billion USD in the first ten months of 2025, reflecting the growing recognition of Chinese drug pipelines by multinational corporations [1] Group 3 - The Hang Seng Innovative Drug ETF (159316) has seen significant capital inflow, with a net inflow of 1.298 billion yuan over the past 20 days, bringing its total size to 4.178 billion yuan [3] - This ETF is the only product tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, focusing on core enterprises in the innovative drug industry, excluding CXO companies [3] - Key weighted stocks in the ETF include leading companies such as BeiGene, Innovent Biologics, WuXi Biologics, and CanSino Biologics, providing investors with a convenient tool for exposure to cutting-edge innovative drug companies in Hong Kong [3]

Core Insights - The company reported a significant increase in revenue and profitability for the first three quarters of 2025, with total revenue reaching RMB 27.595 billion, a year-on-year growth of 44.2%, and a net profit attributable to shareholders of RMB 1.139 billion, marking a turnaround from a loss to profit [3][4] Revenue Breakdown - The global revenue for the drug Zebutini (BTK) reached USD 1.04 billion in Q3 2025, reflecting a year-on-year increase of 50.8% and a quarter-on-quarter increase of 9.6% [4] - In the U.S., Zebutini generated USD 740 million, up 46.7% year-on-year and 8.0% quarter-on-quarter [4] - European sales of Zebutini amounted to USD 160 million, showing a year-on-year growth of 67.7% and a quarter-on-quarter increase of 8.4% [4] - In China, Zebutini's revenue was USD 90 million, with a year-on-year increase of 36.3% and a quarter-on-quarter rise of 11.1% [4] - The company anticipates a 5-10% growth in Zebutini's revenue in Q4 2025, projecting total global revenue for the drug to exceed USD 3.9 billion for the year [4] Profitability Forecast - The company has revised its revenue forecasts for FY25-27 to USD 5.3 billion, USD 6.4 billion, and USD 7.1 billion respectively, indicating a compound annual growth rate (CAGR) of 23% over three years [3] - The net profit forecasts for FY25-27 have also been adjusted to USD 360 million, USD 660 million, and USD 1.05 billion respectively, reflecting better-than-expected growth in sales and R&D expenses [3]

港股创新药板块连续第二日上涨，百济神州涨7%，创2021年11月以来新高，映恩生物、信达生物、三 生制药分别涨7%、6.07%和5%，带动港股通创新药ETF南方(159297)上涨3.37%，录得两连阳。 消息面上，百济神州第三季度营收100.77亿元，同比增长41.1%；归属于上市公司股东的净利润6.89亿 元，同比扭亏为盈。前三季度营收275.95亿元，同比增长44.2%；归属于上市公司股东的净利润11.39亿 元，同比扭亏为盈。 国泰海通证券最新研报指出，全链条鼓励创新政策将进一步改善医保支付，商保创新药目录即将落地， 创新品种仍将是医药板块业绩最强劲的领域。外需方面，大品种专利悬崖的大背景下，MNC的BD交易 活跃，中国已成为全球TOP 20 MNC第二大项目来源地，2026年BD有望再创新高。 港股通创新药ETF南方(159297)跟踪国证港股通创新药指数，重仓百济神州、信达生物、康方生物等研 发实力强劲的中国创新药龙头，该ETF自9月22日上市以来的33日个交易日获资金"只进不出"，合计净 流入10.53亿元，份额新增11.62亿份，增长率高达285.91%，且产品管理费率+托管费率合计为0.2% ...